openPR Logo
Press release

Autologous Stem Cell and Non-Stem Cell Based Therapies Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2017–2025

06-27-2017 06:14 PM CET | Health & Medicine

Press release from: Biotechnology Industry Report By CMI

Autologous Stem Cell and Non-Stem Cell Based Therapies Market

Autologous stem-cell transplantation (also known as autogeneic, autogenic, or autogenous stem-cell transplantation or auto-SCT) is the autologous transplantation of stem cells—which is, transplantation in which the undifferentiated cells or stem cells (cells from which other types of cells develop) are taken from a person, accumulated, and given back to the same person later. Even though it is most often executed by means of hematopoietic stem cells (antecedent of cells that forms blood) in hematopoietic stem cell transplantation, in some cases cardiac cells are used productively to fix the damages due to heart attacks. Stem cell transplantation can be of two types - Autologous stem-cell transplantation and allogenic stem cell transplantation. In the later, the recipient and the donor of stem cells are dissimilar people. In a good number of allogeneic transplants, the stem cells are taken from a donor whose cell type matches closely with the patient’s cell type. The best donor in allogenic stem cell transplantation is an immediate family member, generally a brother or sister. If the patient does not have a match in his/her family, a donor may be found from the public. This is often called a MUD or matched unrelated donor transplant. This type of transplant (MUD) is generally riskier.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/523

Autologous stem cell and non-stem cell based therapies market Taxonomy

On the basis of application, the global autologous stem cell and non-stem cell based therapies market is classified into:

Neurodegenerative diseases
Cardiovascular diseases
Cancer and autoimmune diseases
Skin transplantation
Infectious disease

A primary driver for this market is the worldwide increase in occurrence of diabetes and cancer, across all age groups. Furthermore, increasing old-age population is another driver, which is anticipated to create a high growth scenario for the market.

Alternatively, factors restraining the market are complications and risks associated with the treatment including diarrhea, nausea, hair loss, vomiting, severe infections, infertility, and heart complications.

Increasing prevalence of cancer will drive the overall autologous stem cell and non-stem cell based therapies market

According to a report by National Cancer Institute, in 2016, around 1,685,210 new cases of cancer were diagnosed in the U.S. alone. Moreover, it was also noted that around 595,690 people died from the disease in the same year. Autologous stem cell and non-stem cell based therapies is likely to become one of the preferred treatment for cancer. As the prevalence of cancer is rising at a considerable rate, the market is likely to grow during the forecast period.

North America, followed by Europe accounted for the major share of the autologous stem cell and non-stem cell based therapies market. This is due to minimization of risks related with the treatment. Moreover, the demand for these treatments is high due to their ability to cure a significant number of infectious diseases. Autologous stem cell and non-stem cell based therapies do not need an outside donor; therefore the treatment is less infectious and convenient. These factors are likely to boost the growth of the market in North America. However, Asia Pacific is expected to show the maximum growth in the forecast period. The demand in this region will be lead by countries such as China, India, Malaysia, and Vietnam. The demand is likely to grow as autologous stem cell and non-stem cell based therapies aid in the efficient management of cardiovascular diseases as well. Growing healthcare infrastructure as well as encouraging tax and reimbursement procedures is also expected to help in the growth of the autologous stem cell and non-stem cell based therapies market in the Asia Pacific.

Click here to know more about this report: https://www.coherentmarketinsights.com/ongoing-insight/autologous-stem-cell-and-non-stem-cell-based-therapies-market-523

Key players in the global autologous stem cell and non-stem cell based therapies market are investing heavily in their research and development activities so as to gain an upper hand in the market. Some of the major players operating in the market are NeoStem, Inc., Aastrom Biosciences, Fibrocell Science, Inc., Genzyme Corporation, BrainStorm Cell Therapeutics, Regeneus Ltd., and Dendreon Corporation.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Autologous Stem Cell and Non-Stem Cell Based Therapies Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2017–2025 here

News-ID: 596276 • Views: 266

More Releases from Biotechnology Industry Report By CMI

The New Research Trial Drives The Shigella Vaccines Market
Shigella is a gram-negative pathogenic enterobacteria that causes severe diarrhea and dysentery in humans. Symptoms associated with Shigella infection includes fever, stomach pain, tenesmus, watery diarrhea, vomiting, dehydration, and convulsions. Various strains of Shigella are encompassed, such as S. dysenteriae, S. flexneri, S. sonnei and S. boydii. Each species of Shigella has different serotypes classified on the basis of the structure of O-antigens repeats that are the polysaccharides moiety of the lipopolysaccharide, a virulence
Flow Cytometry Market to Surpass US$ 7.64 Billion Threshold by 2025
Flow Cytometry – It’s not just for immunologist anymore Flow cytometry is a widely used method for analyzing the expression of cell surface and intracellular molecules. It can also characterize and define different cell types in a heterogeneous cell population. Moreover, flow cytometry also allows simultaneous multi-parameter analysis of single cells. The growth in flow cytometry market is mainly driven by the combination of technological improvements, growing research activities in life
Dental Bone Graft and Substitutes Market to Surpass US$ 911.4 Million Threshold …
Dental Bone Graft and Substitutes Market Insights Dental bone grafts are used as fillers or scaffolds that facilitate bone formation and helps in the wound healing and are suitable for a variety of clinical procedures such as filling of sockets, preservation of ridge volume (also referred to as ridge preservation), and osteogenesis i.e., the formation of new bones. Dental bone grafts are bioresorbable and are not reactive to antigen-antibody. Bone grafts
Dental Bone Graft and Substitutes Market to Surpass US$ 911.4 Million Threshold …
Dental Bone Graft and Substitutes Market Insights Dental bone grafts are used as fillers or scaffolds that facilitate bone formation and helps in the wound healing and are suitable for a variety of clinical procedures such as filling of sockets, preservation of ridge volume (also referred to as ridge preservation), and osteogenesis i.e., the formation of new bones. Dental bone grafts are bioresorbable and are not reactive to antigen-antibody. Bone grafts

All 5 Releases


More Releases for Autologous

Autologous Matrix-induced Chondrogenesis Market: Report Scope and Market Segment …
The global autologous matrix-induced chondrogenesis (AMIC) market has been expected in a publication prepared by Transparency Market Research (TMR) to witness strategies aimed toward business expansion in developing economies. Countries such as South Africa, Mexico, China, India, and Brazil could be focused upon by AMIC players for gaining a strategic position in the market. This has been anticipated to help companies reduce their AMIC product costs supported by the hiring
Autologous Matrix-induced Chondrogenesis Market : Share and Analysis To 2025
Global Autologous Matrix-induced Chondrogenesis Market: Overview Autologous matrix-induced chondrogenesis (AMIC) refers to a type of treatment for the damage of articular cartilage. The treatment blends the application of a bi-layer collagen I/III membrane with micro fracture surgery. The treatment refers to a single step procedure that makes use of micro fracturing method and that is a well-established first line of treatment. The world AMIC market is foreseen to grow owing to the
Autologous Matrix-Induced Chondrogenesis Market Estimated to Flourish by 2024
Autologous Matrix-Induced Chondrogenesis (AMIC) is a biological treatment method to repair articular cartilage damage. AMIC therapy is a step wise process. Micro fracture surgery is followed by application of a bi-layer collagen I/III membrane. It slows down cartilage degeneration with an intent to avoid or delay partial or total joint replacement (e.g. knee replacement) surgery. The indications for AMIC includes Grade III or IV chondral lesions with lesion size of
Autologous Matrix-induced Chondrogenesis Market Research Report Forecast to 2024
The global AMIC market to rise at a CAGR of 8.6% between 2016 and 2024 to achieve a revenue valuation of US$186.38 mn by the concluding forecast year. In 2015, the market had reached a US$89.71 mn. By material, the AMIC market for collagen could attain a higher share of almost 50.0% by 2024. Calculated to develop at an 8.3% CAGR, North America has been predicted to be a highly
Autologous Cell Therapy Market : Trend, Analysis
Global Autologous Cell Therapy Market: Overview Autologous cell therapy refers to infusion or transfer of human tissue or cells back to the same person for treating a diseased part. For the same purpose, stem cells are removed from the patient, harvested, cultured, and once again transplanted to the same person. The purpose of this method is to reduce the chances of rejection to the treatment by the body. Furthermore, autologous cell
Autologous Cell Therapy Market: High Prevalence of Cancer Triggers Demand for Au …
Global Autologous Cell Therapy Market: Overview Autologous cell therapy refers to infusion or transfer of human tissue or cells back to the same person for treating a diseased part. For the same purpose, stem cells are removed from the patient, harvested, cultured, and once again transplanted to the same person. The purpose of this method is to reduce the chances of rejection to the treatment by the body. Furthermore, autologous cell